期刊文献+

自拟中药汤联合非索非那定、匹多莫德治疗难治性慢性特发性荨麻疹的疗效观察及安全性分析 被引量:5

Efficacy and Safety of Self-Made Traditional Chinese Medicine Decoction Combined with Fexofenadine and Pidotimod in Treatment of Refractory Chronic Idiopathic Urticaria
原文传递
导出
摘要 目的分析自拟中药汤联合非索非那定、匹多莫德治疗难治性慢性特发性荨麻疹的疗效及安全性。方法选择我院2015年3月-2016年4月期间收治的68例慢性特发性荨麻疹患者作为研究对象,随机将其分为观察组与对照组,各34例。对照组患者予以服用非索非那定联合匹多莫德治疗,观察组在西药治疗的基础上加用中药汤治疗。比较两组患者治疗后的临床疗效及不良反应发生率。结果观察组患者的有效率为94.12%,显著高于对照组的67.65%,差异有统计学意义(P<0.05);治疗后,观察组CRP、IgG、IgE及EOS水平均低于对照组,差异有统计学意义(P<0.05);治疗后观察组CD3^+、CD4^+、CD8^+及CD4^+/CD8^+指标水平均高于对照组,差异有统计学意义(P<0.05);治疗前后检查血常规、尿常规、肝、肾功能,观察组不良反应发生率为5.88%,低于对照组的23.53%,差异有统计学意义(P<0.05)。结论采用自拟中药汤联合非索非那定、匹多莫德治疗难治性慢性特发性荨麻疹取得较为理想的临床效果,且治疗中不良反应少,安全性较高,有助于提高患者的生活质量。 Objective To analyze the efficacy and safety of self-made traditional Chinese medicine (TCM) decoction combined with fexofenadine and pidotimod in treatment of refractory chronic idiopathic urticaria (CIU).Methods 68 CIU patients admitted into our hospital from March 2015 to April 2016 were randomly divided into observation group and control group,34 cases in each.Control group took fexofenadine and pidotimod,observation group took TCM decoction on the basis of western medicine.The clinical efficacy and incidence of adverse reactions of two groups after treatment were compared.Results The effective rate of observation group was 94.12%,significantly higher than 67.65% of control group (P〈0.05);After treatment,the observation group CRP,IgG,IgE and EOS were significantly lower than control group,significant difference (P〈0.05);after treatment,the observation group CD3+,CD4+,CD8+ and CD4+/CD8+ levels were significantly higher than the control group,the difference was significant (P〈0.05).Before and after treatment the blood routine,urine routine,liver and renal function,the incidence of adverse reactions was 5.88%,significantly lower than the control group 23.53%,the difference was statistically significant (P〈0.05).Conclusion Self-made TCM decoction combined with fexofenadine and pidotimod for refractory CIU can achieve satisfactory clinical effects with less adverse reactions and high safety,which is beneficial to improve patients' living quality.
出处 《辽宁医学杂志》 2017年第2期20-21,24,共3页 Medical Journal of Liaoning
关键词 中药 非索非那定 匹多莫德 难治性慢性特发性荨麻疹 Traditional Chinese medicine Fexofenadine Pidotimod Refractory chronic idiopathic urticaria
  • 相关文献

参考文献8

二级参考文献79

  • 1姜秀英,蒋忠民,李景华.斯奇康与皿治林联合治疗慢性荨麻疹疗效评价[J].吉林大学学报(医学版),2006,32(3):509-510. 被引量:3
  • 2刘丽丽,张焕梅,刘志军.衡阳地区575例慢性荨麻疹患者过敏原检测分析[J].实用全科医学,2007,5(5):381-382. 被引量:5
  • 3Drichard B, William D, Timothy G. Andrew's Diseases of the- Skin[M]. 9th ed. 北京:科学出版社,2001:161.
  • 4谷锋.依巴斯汀和转移因子联合治疗慢性荨麻疹的临床观察[J].中国现代医学,2011,49(16):74-75.
  • 5Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2 ) LEN/EDF/WAO guideline: definition, classification anddiagnosis of urticaria. Allergy, 2009,64( 10 ): 1417-1426.
  • 6Vohra S, Sharma NL,Mahajan VK. Autologous serum skin test:methodology, interpretation and clinical applications. Indian JDermatol Venereol Leprol, 2009,75(5): 545-548.
  • 7Huilan Z, Runxiang L,Bihua L, et al. Role of the subgroups ofT, B, natural killer lymphocyte and serum levels of interleukin-15, interleukin-21 and immunoglobulin E in the pathogenesis ofurticaria. J Dermatol, 2010, 37(5): 441-447.
  • 8Grattan CE, Wallington TB, Warin HP, et al. A serological medi-ator in chronic idiopathic urticaria: a clinical, immunologicaland histological evaluation. Br J Dermatol, 1986,114 (5): 583-590.
  • 9Vohra S,Sharma NL, Mahajan VK. Autologous serum skintest: methodology, interpretation and clinical applications. Indi-an J Dermatol Venereol Leprol, 2009, 75(5): 545-548.
  • 10Sajedi V, Movahedi M, Aghamohamadi A, et al. Comparisonbetween sensitivity of autologous skin serum test and autolo-gous plasma skin test in patients with Chronic Idiopathic Urticariafor detection of antibody against IgE or IgE receptor(FceRIa). Iran J Allergy Asthma Immunol, 2011, 10(2):111-117.

共引文献101

同被引文献72

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部